Sign Up to like & get
recommendations!
0
Published in 2020 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2020.10.031
Abstract: OBJECTIVE Immune checkpoint blockade (ICB) therapy shows limited efficacy in ovarian cancers due to the "cold" immune phenotype surrounding these tumors. Previous studies have shown that in ovarian cancer Wnt/β-catenin pathway activation contributes to this…
read more here.
Keywords:
icb therapy;
cgx 1321;
ovarian cancer;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.2c02490
Abstract: The immune checkpoint blockade (ICB) therapy based on monoclonal antibodies still suffers from a lower immune response rate and severe immune-related side effects, which greatly compromise its therapeutic benefits. Herein, ultrasound (US) microbubbles (MBs) that…
read more here.
Keywords:
icb therapy;
pcf mbs;
conversion;
situ micro ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Nucleic Acids Research"
DOI: 10.1093/nar/gkac374
Abstract: Abstract Immune checkpoint blockade (ICB) therapy has been successfully applied to clinically therapeutics in multiple cancers, but its efficacy varies greatly among different patients and cancer types. Therefore, the construction of gene signatures to identify…
read more here.
Keywords:
tirsf;
icb therapy;
immunotherapy;
gene signatures ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-22-0249
Abstract: Immune checkpoint blockade (ICB) therapy provides remarkable clinical benefits for multiple cancer types. Much work is currently being conducted to investigate the mechanisms of ICB therapy at the transcriptional level. Integrating the data produced by…
read more here.
Keywords:
icb therapy;
immune checkpoint;
therapy;
response ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Clinical Epigenetics"
DOI: 10.1186/s13148-020-00907-4
Abstract: Background It is crucial to unravel molecular determinants of responses to immune checkpoint blockade (ICB) therapy because only a small subset of advanced non-small cell lung cancer (NSCLC) patients responds to ICB therapy. Previous studies…
read more here.
Keywords:
clinical benefit;
lung cancer;
icb therapy;
methylation patterns ... See more keywords